Overview
In a market where efficiencies, cost savings, repeatable processes and safety are vital, cell and gene therapy companies must routinely evaluate their processes and analyze where improvements can be made, even down to the way they are managing fluid transfer.
CPC examines the total cost of ownership of tube welded connections and single-use aseptic connectors. In this presentation he discusses vital evaluating criteria such capital expenditure, raw materials and utilities, but also dives deeper into considerations such as training, downtime, validations, and connection speed.